JP2024513514A5 - - Google Patents
Info
- Publication number
- JP2024513514A5 JP2024513514A5 JP2023562500A JP2023562500A JP2024513514A5 JP 2024513514 A5 JP2024513514 A5 JP 2024513514A5 JP 2023562500 A JP2023562500 A JP 2023562500A JP 2023562500 A JP2023562500 A JP 2023562500A JP 2024513514 A5 JP2024513514 A5 JP 2024513514A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172424P | 2021-04-08 | 2021-04-08 | |
| US63/172,424 | 2021-04-08 | ||
| US202163290351P | 2021-12-16 | 2021-12-16 | |
| US63/290,351 | 2021-12-16 | ||
| PCT/US2022/023676 WO2022216826A1 (en) | 2021-04-08 | 2022-04-06 | Treatment of cancer with nk cells and a cd38-targeted antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024513514A JP2024513514A (ja) | 2024-03-25 |
| JP2024513514A5 true JP2024513514A5 (https=) | 2025-04-14 |
| JPWO2022216826A5 JPWO2022216826A5 (https=) | 2025-04-14 |
Family
ID=83546555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562500A Withdrawn JP2024513514A (ja) | 2021-04-08 | 2022-04-06 | Ｎｋ細胞およびｃｄ３８－標的抗体を用いた癌治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240115704A1 (https=) |
| EP (1) | EP4319770A4 (https=) |
| JP (1) | JP2024513514A (https=) |
| KR (1) | KR20240024047A (https=) |
| AU (1) | AU2022253256A1 (https=) |
| WO (1) | WO2022216826A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| EP3633029A4 (en) | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| US12116417B2 (en) | 2017-11-14 | 2024-10-15 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| MY199770A (en) | 2018-11-14 | 2023-11-22 | Green Cross Lab Cell Corp | Method for culturing cord blood-derived natural killer cells using transformed t cells |
| CN116679065B (zh) * | 2023-07-31 | 2023-11-14 | 北京大学人民医院 | 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3083779A1 (en) * | 2017-12-22 | 2019-06-27 | Fate Therapeutics, Inc. | Enhanced immune effector cells and use thereof |
| WO2019201629A1 (en) * | 2018-04-19 | 2019-10-24 | Onkimmune Limited | Nk cells for use with antibodies in cancer therapy |
| EP4474391A3 (en) * | 2018-05-14 | 2025-02-26 | Indapta Therapeutics, Inc. | Subsets of human natural killer cells with enhanced antibody-directed immune responses |
| WO2020101361A1 (ko) * | 2018-11-14 | 2020-05-22 | 주식회사 녹십자랩셀 | 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법 |
| US20210171650A1 (en) * | 2019-05-14 | 2021-06-10 | Sanofi | Methods of administering anti-cd38 antibody |
-
2022
- 2022-04-06 AU AU2022253256A patent/AU2022253256A1/en not_active Abandoned
- 2022-04-06 US US18/285,646 patent/US20240115704A1/en active Pending
- 2022-04-06 EP EP22785374.4A patent/EP4319770A4/en active Pending
- 2022-04-06 KR KR1020237038592A patent/KR20240024047A/ko not_active Withdrawn
- 2022-04-06 JP JP2023562500A patent/JP2024513514A/ja not_active Withdrawn
- 2022-04-06 WO PCT/US2022/023676 patent/WO2022216826A1/en not_active Ceased